About Parkinson’s Disease
Parkinson’s disease is the second most common neurodegenerative movement disorder, next to Alzheimer’s. With the currently increasing geriatric population, there will be an increase in the number of patients diagnosed with Parkinson’s disease. Increasing awareness about the disease along with other neurological movement related diseases have created space for growth in the deep brain stimulation devices market. About 12 percent of deaths worldwide are caused due to neurodegenerative diseases, of which 85 percent are cerebrovascular.
Browse Deep Brain Stimulation Devices Market Research Report with complete TOC at http://www.transparencymarketresearch.com/deep-brain-stimulator-market.html
Treatment Methods for Parkinson’s
The most effective treatment method for controlling initial stage Parkinson’s disease is drug therapy. The amount and potency of drugs required to control Parkinson’s disease at a late stage are substantial, which is why Deep Brain Stimulation (DBS) can prove to be a better option.
DBS is a surgical treatment used to control the involuntary symptoms of Parkinson’s disease. DBS is and FDA approved, clinically proven and effective treatment option for mild to severe Parkinson’s disease. The Deep Brain Stimulation device market is expected to expand at a positive rate between 2013 and 2019.
Get Free Sample Report at http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1435
DBS Market Drivers and Restraints
The increasing number of patients diagnosed with Parkinson’s disease is the prime growth driver for the DBS device market. As a larger percentage of the population approaches old age, the increasing risk and prevalence of Parkinson’s disease could prompt the top medical organizations and governments to help research for more effective techniques. DBS remains one of the more effective treatment methods currently. Other treatment options for Parkinson’s disease include:
- Stem cell therapy
- Surgical treatment
- Physical therapy
- Some of the common drug therapies include the use of:
- Dopamine agnostics
- MAO-B inhibitors
- Catechol-O-methyltransferase (COMT) inhibitors
Browse More Medical Devices Related Research Reports at http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html
One of the greatest disadvantages of drug therapy is that prolonged usage will weaken their effects. Once their effectiveness starts reducing, they become nothing more than a costly redundancy for most patients, who then start looking for other options. Surgical treatment becomes the leading option for later stages of Parkinson’s disease, which makes DBS a far safer surgical option than other open surgeries such as pallidotomy, thalamotomy and subthalamotomy.
The key restraint for the DBS market is the involvement of high costs in the surgical equipment and procedure which discourages many patients to resort to drug therapy instead. Many original equipment manufacturers have responded to the increasing burden of Parkinson’s disease on healthcare facilities and governments, and have developed advanced research labs to study better methods of treating Parkinson’s disease.